Hamilton Lane Inc Stock Price, News & Analysis

Hamilton Lane (Nasdaq: HLNE), a leading private markets investment firm, will release its first quarter fiscal 2026 financial results on August 5, 2025, before market opens. The company will host a conference call and webcast at 11:00 a.m. ET the same day.

Hamilton Lane manages approximately $958 billion in assets, including $138 billion in discretionary assets and $819 billion in non-discretionary assets as of March 31, 2025. The firm employs about 760 professionals across offices in North America, Europe, Asia Pacific, and the Middle East, specializing in private markets investing for over 30 years.

Hamilton Lane (NASDAQ: HLNE) has announced the launch of its Asia Private Assets Fund (HLAPA), a pioneering semi-liquid vehicle designed to provide investors access to Asia's $3+ trillion private equity market. The fund represents a significant expansion of Hamilton Lane's $11 billion Evergreen Platform.

The HLAPA fund features a flexible portfolio construction focusing on private equity through direct investments and secondaries. Key features include immediate capital deployment without capital calls, lower minimum investments compared to traditional drawdown funds, monthly subscriptions, and potential quarterly liquidity subject to terms. The fund leverages Hamilton Lane's 15-year experience in Asian markets and aims to provide diversified exposure across Australia, Japan, Korea, India, Southeast Asia, and China.

The fund's first dealing date for subscriptions is targeted for September 1, 2025. This launch marks Hamilton Lane's latest addition to its Evergreen Platform, which launched in 2019 and now includes nine funds across multiple strategies.

Cosette Pharmaceuticals (NYSE:HLNE) has appointed Jeff Neubig as Vice President of Quality and Regulatory Affairs. The appointment comes as the company continues to strengthen its quality and regulatory capabilities following 24 new product launches over the last three years with zero major quality observations.

Neubig brings over 35 years of pharmaceutical industry experience, including 25 years leading quality assurance, quality control, and regulatory affairs teams. Prior to joining Cosette, he served as Vice President of Quality and Regulatory Affairs, North America at LTS Lohmann Therapy Systems, where he managed multiple successful regulatory inspections and provided guidance for IND, NDA, and ANDA products.

The new executive holds a Ph.D. in Evolution, Ecology and Organismal Biology from The Ohio State University, an MS in Biology from Montclair State University, and a Bachelor's degree in Biology from Mount Saint Mary's College.

Banner Capital Management has announced two significant developments: the closing of Fund I, a $400 million multi-asset continuation fund, and the launch of Fund II, targeting $200 million for lower middle market buyouts. Hamilton Lane (HLNE) is leading Fund I as the primary investor, which will acquire interests in eight pre-fund portfolio companies. The recapitalization provides additional time and capital for portfolio companies while offering partial liquidity to pre-fund investors. Fund II has already held a preliminary closing to facilitate the Western Pavement Services transaction, with support from the Larry H. & Gail Miller Family Foundation and other legacy LPs. A traditional first closing for Fund II is expected in Q4 2025.

Hamilton Lane (HLNE) reported strong financial results for FY2025. The company's assets under management grew 11% year-over-year to $138 billion, while fee-earning assets increased 10% to $72 billion. Management and advisory fees rose 14% to $513.9 million. The company achieved GAAP earnings per share of $5.41 on net income of $217.4 million. Hamilton Lane declared a quarterly dividend of $0.54 per share, with a target full-year dividend of $2.16, representing a 10% increase from the previous fiscal year. The company's unrealized carried interest balance grew 3% to $1.3 billion. As of March 31, 2025, Hamilton Lane managed $957.8 billion in total assets under management and supervision, including $138.3 billion in discretionary assets and $819.5 billion in non-discretionary assets.

Hamilton Lane (HLNE) has invested in IMM Infra 8th Private Equity Fund through a secondary transaction completed on March 31, 2025. The deal involves acquiring existing Limited Partner interests and marks IMM Investment's first infrastructure-focused secondary deal in Asia. The fund focuses on core-plus and value-added infrastructure investments across Korea's energy, mobility, digital, and social infrastructure sectors. The partnership combines IMM's local expertise with Hamilton Lane's global secondaries capabilities. This strategic move highlights growing institutional interest in Korean infrastructure assets and represents IMM Investment's expansion from a Korea-focused asset manager to a regional platform through its Singapore hub, established in 2023.

Hamilton Lane (HLNE) has announced it will release its financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2025, on May 29, 2025, before market opens. The company will host a conference call and webcast at 11:00 a.m. ET on the same day to discuss the results.

Hamilton Lane is a leading private markets investment firm with $956 billion in assets under management and supervision, including $135 billion in discretionary assets and over $821 billion in non-discretionary assets as of December 31, 2024. With approximately 740 professionals across offices worldwide, the firm has been dedicated to private markets investing for more than 30 years, offering innovative solutions to institutional and private wealth investors globally.

Hamilton Lane (NASDAQ: HLNE) has launched the Hamilton Lane Venture Capital and Growth Fund (HLVCG), a new evergreen investment vehicle registered under the Investment Act of 1940. The fund provides accredited U.S. investors access to private venture capital and growth equity investments, focusing on disruptive technologies and innovative companies.

The fund leverages Hamilton Lane's extensive experience in private markets, with the firm managing $117.8 billion in assets and maintaining over 260 relationships spanning more than 370 investments in the venture and growth equity space. HLVCG is part of Hamilton Lane's broader $10+ billion AUM Evergreen Platform and offers features such as upfront capital deployment, flexible liquidity options, and portfolio diversification across vintage year, transaction type, manager, strategy, and geography.

Grenova, a Virginia-based sustainable laboratory technologies company, has announced two major developments: the appointment of Ted Hull to its board and the completion of a new growth equity capital round. Hull brings over 30 years of life sciences experience, including 20+ years as a clinical lab CEO.

The new funding, led by Peloton Equity and Hamilton Lane's (Nasdaq: HLNE) Impact Fund II, along with other existing investors, will be utilized to enhance Grenova's automation portfolio, expand R&D capabilities, and grow the team to meet global market demand. The company focuses on transforming single-use laboratory plastics into sustainable, reusable solutions.